Please login to the form below

Not currently logged in
Email:
Password:

Idalopirdine

This page shows the latest Idalopirdine news and features for those working in and with pharma, biotech and healthcare.

Lundbeck signs $1.1bn deal for Prexton and Parkinson’s drug

Lundbeck signs $1.1bn deal for Prexton and Parkinson’s drug

the failure of Alzheimer’s candidate idalopirdine.

Latest news

  • Axovant joins ever-growing Alzheimer’s failure club Axovant joins ever-growing Alzheimer’s failure club

    5-HT6 inhibitor Intepirdine followsin the footsteps of Lundbeck's idalopirdine. Axovant’s phase III trial of Alzheimer’s disease (AD) candidate intepirdine has ended in failure, an outcome that ... s idalopirdine, which suffered a similar late-stage

  • Lundbeck trial failure dashes hopes in Alzheimer's once again Lundbeck trial failure dashes hopes in Alzheimer's once again

    Idalopirdine (Lu AE58054) appeared to be safe and showed evidence of "weak efficacy" in the phase III STARSHINE study, which enrolled patients with mild to moderate Alzheimer's. ... Idalopirdine is being developed in partnership with Japanese drugmaker

  • Surging sales of Lundbeck's CNS drugs assist recovery Surging sales of Lundbeck's CNS drugs assist recovery

    new Otsuka-partnered drug - idalopirdine - in trials for Alzheimer's disease. ... Idalopirdine (Lu AE58054) is being tested as an add-on therapy to boost the effects of cholinesterase inhibitors in Alzheimer's, so could be a less risky proposition than

  • Axovant takes Alzheimer's drug into phase III Axovant takes Alzheimer's drug into phase III

    Lundbeck and Otsuka also have a 5-HT6 antagonist called idalopirdine (Lu AE58054) in phase III trials that are due to report data between November and mid-2016.

More from news
Approximately 2 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics